Significados de systemic embolism en inglés

Atrial fibrillation is frequent and may have catastrophic consequences, including systemic embolism.

Analysis of stroke or systemic embolism was based on intention to treat.

Patients were excluded if other causes of systemic embolism were found.

The primary outcome was ischemic or hemorrhagic stroke or systemic embolism.

The primary efficacy end point was stroke or systemic embolism.

The secondary end point was systemic embolism during treatment.

The primary efficacy outcome was stroke or systemic embolism; the primary safety outcome was major bleeding.

Rates of stroke or systemic embolism, major bleeding, and all-cause mortality increased as renal function decreased.

Furthermore, 50 per cent of patients with an aneurysm of the interatrial septum had a history of systemic embolism.

Dabigatran is a direct thrombin inhibitor that reduces the risk of systemic embolism in patients with nonvalvular atrial fibrillation.

Other patients at risk for systemic embolism include those with chronic left ventricular aneurysm, chronic dilated cardiomyopathy, and cardiac tumors.

Annualized event rates of stroke or systemic embolism and major bleeding and hazard ratios (HRs) and 95% CIs were evaluated.

Our aim was to review observational studies on this subject to identify prognostic factors and to compare mortality and systemic embolism between treatments.

Surgical thromboembolectomy showed a nonsignificant trend toward improved survival, significantly reduced systemic embolism, and composite of mortality and systemic embolism, compared with anticoagulation alone.

Conclusions: In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.

Conclusion: Higher CHADS(2) scores were associated with increased risks for stroke or systemic embolism, bleeding, and death in patients with atrial fibrillation receiving oral anticoagulants.